Managing Team
Stefano Iacobelli, MD – Co-Founder, President and Chief Executive Officer
Dr. Stefano Iacobelli was Professor of Medical Oncology at the University “G. D’Annunzio” of Chieti-Pescara, Italy and Coordinator of the PhD program in Molecular Pathology and Oncology. Presently, he is coordinating the research activity at the Polyclinic A. Gemelli/Catholic University, Rome Italy. Dr. Iacobelli has more than 30 years of experience in the translational and clinical oncology. He started his career in academic medicine, trained in Europe and the Canada, received board certifications for medical oncology. He served as Associate Professor of Clinical Oncology at the Catholic University, Rome, Italy; then he became Full Professor of Medical Oncology, Head of Cancer Clinic and Coordinator, PhD Program in Molecular and Clinical Oncology at the University “G. D’Annunzio”. He was founder and Director of the National Consortium for Cancer Research (CINBO), a network of 18 Universities focusing on translational research on oncology and founder and President of Mediterranean Task Force for Cancer Control (MTCC). Dr. Iacobelli was in the team of Sugen Inc., later sold to Pfizer and was cofounder at U3 Pharm AG, a German biotechnology company focusing on research into antibodies for the treatment of cancer, later sold to Daiichi-Sankyo Co, Ltd. Dr. Iacobelli main research interests includetumor growth control mechanisms, hormone receptor functions and pre-clinical and clinical development of anticancer drugs. Presently, Dr. Iacobelli is focusing on the discovery and development of monoclonal antibodies and antibody-drug conjugates. He is author of over 250 publications in international peer reviewed journals and co-inventor in 15 patents.
Pier Giorgio Natali, MD, PhD – Vice-President, Chief Scientific Officer, Immunology & Precision Medicine
Dr. Natali is Professor of Medicine and Oncology. He graduated from “La Sapienza” University of Rome, Italy, and trained in Experimental Immunopathology in the USA and has focused his scientific career in basic and translational oncology. As President of the Italian Cancer Society and Scientific Director of the “Regina Elena”, a leading nationwide comprehensive cancer center in Italy, he has also contributed to many areas of the fight against cancer including prevention, early diagnosis, education and advocacy. He has served in strategic international boards and Co-Founded the Chart of Paris. Dr. Natali has published over 350 studies with high citation record. He is presently Fellow of the Collegium Ramazzini and served in the Advisory Board of Cancer Today Magazine, edited by the AACR. He is also the Secretary General of Mediterranean Task Force for Cancer Control (MTCC). He has published over 350 studies with high Citation Index.
Jean-Frederic Sauniere, MD, PhD – VP Business Development, Chief Operating Officer
Dr. Jean-Frederic Sauniere, medical oncologist, obtained his MD and PhD from the University
of Medicine, Marseille, France. Dr. Sauniere brings 25 years of experience in translational, clinical research and drug development. He served as Director of Clinical Research, then Director of Corporate Licensing & Business development at Pfizer, New York and as Vice-President of Anaderm, a subsidiary of Pfizer. Dr. Sauniere was an executive in several early stage pharmaceutical companies in the US and CEO of Shogoo Pharmaceuticals in Basel, Switzerland.
Bernard Geudelin, MD – Chief Medical Officer
Dr. Bernard Geudelin obtained his M.D. in Paris, France. He is an expert in clinical research, pharmacology and internal medicine. Dr. Geudelin has worked in various senior medical and clinical research positions at Hoffman La Roche, Sanofi Switzerland, Actelion Pharmaceuticals. Dr. Geudelin is co-founder of Mediante, a swiss CRO conducting in particular clinical trials in oncology throughout Europe.
Antonio Zangrilli, PhD – Director Regulatory Affairs
Dr. Zangrilli received his degree in Economics at the University “La Sapienza” of Rome, Italy and post-graduate degree in Export Management at the Institute for Foreign Trade (I.C.E.) in Rome, Italy. He gained a strong expertise in the field of technology transfer services of the DGs of the European Commission and consulting services to innovative companies. He has acquired a strong experience in the development of market analysis and exploitation strategies for innovative technologies. Dr. Zangrilli is co-founder and President of the Invent Srl seed-capital funds, which invested in MediaPharma.
related pages:
